Helen Kelly (Spain)
Catalan Institute of Oncology (ICO) – Bellvitge Biomedical Research Institute (IDIBELL) Cancer Epidemiology Research Program
Presenter of 2 Presentations
HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN LIVING WITH HIV (ID 709)
Session Time
13:15 - 14:45
Session Type
Clinical Science Oral Session
Lecture Time
13:54 - 14:06
[{"name":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 709)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":709,"presentation":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 709)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Helen Kelly (Spain)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/93.jpg"},"playlist":[{"name":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN L","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/9D566837.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"6E22UU0de"}
[session]
[presentation]
[presenter]
Hide
Introduction by Chairs (ID 1711)
Session Time
13:30 - 14:55
Session Type
Interdisciplinary
Lecture Time
13:30 - 13:33
Moderator of 3 Sessions
Session Type
Interdisciplinary
Session Time
13:30 - 14:55
Session Type
Clinical Science Oral Session
Session Time
13:15 - 14:45
[{"name":"LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CANCER RISK \u003Csmall\u003E(ID 1352)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1352,"presentation":"LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CANCER RISK \u003Csmall\u003E(ID 1352)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Megan Clarke (United States of America)","photo":""},"playlist":[{"name":"LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CANCER RISK Megan Clarke 1352.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CANCER RISK Megan Clarke 1352.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/7B0A0D9B.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/LONGITUDINAL PATTERNS OF HPV18 AND HPV45 METHYLATION AND ASSOCIATIONS WITH CERVICAL PRECANCER AND CANCER RISK Megan Clarke 1352.vtt"}]},{"name":"EFFECTIVE METHYLATION TRIAGE OF HPV-POSITIVE WOMEN WITH ABNORMAL CYTOLOGY IN A MIDDLE-INCOME COUNTRY \u003Csmall\u003E(ID 417)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":417,"presentation":"EFFECTIVE METHYLATION TRIAGE OF HPV-POSITIVE WOMEN WITH ABNORMAL CYTOLOGY IN A MIDDLE-INCOME COUNTRY \u003Csmall\u003E(ID 417)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Gloria I. Sanchez (Colombia)","photo":""},"playlist":[{"name":"EFFECTIVE METHYLATION TRIAGE OF HPV-POSITIVE WOMEN WITH ABNORMAL CYTOLOGY IN A MIDDLE-INCOME COUNTRY","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/417.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/417.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/3E07C286.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/417.vtt"}]},{"name":"NON-INVASIVE METHYLATION TEST TO DETECT CERVICAL PRE-CANCER IN SELF-COLLECTED VAGINAL AND URINE SPECIMENS. \u003Csmall\u003E(ID 210)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":210,"presentation":"NON-INVASIVE METHYLATION TEST TO DETECT CERVICAL PRE-CANCER IN SELF-COLLECTED VAGINAL AND URINE SPECIMENS. \u003Csmall\u003E(ID 210)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Belinda Nedjai (United Kingdom)","photo":""},"playlist":[{"name":"NON-INVASIVE METHYLATION TEST TO DETECT CERVICAL PRE-CANCER IN SELF-COLLECTED VAGINAL AND URINE SPEC","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/IPVC20 - Belinda Nedjai - P210 - S600 - new.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/IPVC20 - Belinda Nedjai - P210 - S600 - new.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/75A8E3A0.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/IPVC20 - Belinda Nedjai - P210 - S600 - new.vtt"}]},{"name":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 709)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":709,"presentation":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN LIVING WITH HIV \u003Csmall\u003E(ID 709)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Helen Kelly (Spain)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/93.jpg"},"playlist":[{"name":"HPV16 VIRAL LOAD AND DNA METHYLATION OF THE HPV16 L1 AND EPB41L3 GENES AMONG HPV-16 POSITIVE WOMEN L","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/9D566837.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/P709_S600_HPV16 VIRAL LOAD AND DNA .vtt"}]},{"name":"THE PERFORMANCE OF HPV 16 DNA METHYLATION AND E6 ONCOPROTEIN IN PREDICTING THE RISK OF CERVICAL PRECANCERS: A 10-YEAR PROSPECTIVE COHORT STUDY \u003Csmall\u003E(ID 953)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":953,"presentation":"THE PERFORMANCE OF HPV 16 DNA METHYLATION AND E6 ONCOPROTEIN IN PREDICTING THE RISK OF CERVICAL PRECANCERS: A 10-YEAR PROSPECTIVE COHORT STUDY \u003Csmall\u003E(ID 953)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Li Dong (China)","photo":""},"playlist":[{"name":"THE PERFORMANCE OF HPV 16 DNA METHYLATION AND E6 ONCOPROTEIN IN PREDICTING THE RISK OF CERVICAL PREC","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/953 First Attempt .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/953 First Attempt .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/2A318D30.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/953 First Attempt .vtt"}]},{"name":"PREDICT AND PRIORITIZE: DETECTION OF CIN3 LESIONS UP TO 5 YEARS BEFORE THEIR DEVELOPMENT USING A METHYLATION CLASSIFIER \u003Csmall\u003E(ID 426)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":426,"presentation":"PREDICT AND PRIORITIZE: DETECTION OF CIN3 LESIONS UP TO 5 YEARS BEFORE THEIR DEVELOPMENT USING A METHYLATION CLASSIFIER \u003Csmall\u003E(ID 426)\u003C\/small\u003E","session":"Oral Session 1: Methylation Potential Use for Clinical Practice","presenter":"Belinda Nedjai (United Kingdom)","photo":""},"playlist":[{"name":"PREDICT AND PRIORITIZE: DETECTION OF CIN3 LESIONS UP TO 5 YEARS BEFORE THEIR DEVELOPMENT USING A MET","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/Belinda Nedaj.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/72\/Belinda Nedaj.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/DC4967E4.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/72\/Belinda Nedaj.vtt"}]}]
{"type":2,"code":"aE32UU02f"}
[session]
[presentation]
[presenter]
Session Type
Public Health Oral Session
Session Time
07:00 - 08:30
[{"name":"INCREASING BURDEN OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV IN THE CONTEXT OF ART \u003Csmall\u003E(ID 1264)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1264,"presentation":"INCREASING BURDEN OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV IN THE CONTEXT OF ART \u003Csmall\u003E(ID 1264)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Darcy W. Rao (United States of America)","photo":""},"playlist":[{"name":"Changes in the burden of cervical cancer among women living with HIV in the context of ART Scale-up","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200619-155400_Darcy-Rao-_1920x1080.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200619-155400_Darcy-Rao-_1920x1080.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/E0936E2A.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200619-155400_Darcy-Rao-_1920x1080.vtt"}]},{"name":"TREND OF THE PREVALENCE OF HIGH-RISK HPV INFECTION AMONG RWANDAN WOMEN LIVING WITH HIV OVER 15 YEARS \u003Csmall\u003E(ID 1095)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1095,"presentation":"TREND OF THE PREVALENCE OF HIGH-RISK HPV INFECTION AMONG RWANDAN WOMEN LIVING WITH HIV OVER 15 YEARS \u003Csmall\u003E(ID 1095)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Gad Murenzi (Rwanda)","photo":""},"playlist":[{"name":"TREND OF THE PREVALENCE OF HIGH-RISK HPV INFECTION AMONG RWANDAN WOMEN LIVING WITH HIV OVER 15 YEARS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/Gad Murenzi-IPVC20-1095.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/Gad Murenzi-IPVC20-1095.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/8B7F336.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/Gad Murenzi-IPVC20-1095.vtt"}]},{"name":"HPV16 E6 SEROPREVALENCE AND TIMING OF SEROCONVERSION BEFORE ANAL CANCER DIAGNOSIS: FINDINGS FROM THE HPVC3 CONSORTIUM \u003Csmall\u003E(ID 392)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":392,"presentation":"HPV16 E6 SEROPREVALENCE AND TIMING OF SEROCONVERSION BEFORE ANAL CANCER DIAGNOSIS: FINDINGS FROM THE HPVC3 CONSORTIUM \u003Csmall\u003E(ID 392)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Nicole Brenner (Germany)","photo":""},"playlist":[{"name":"HPV16 E6 SEROPREVALENCE AND TIMING OF SEROCONVERSION BEFORE ANAL CANCER DIAGNOSIS: FINDINGS FROM THE","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/IPVC PRESENTATION ID 392.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/IPVC PRESENTATION ID 392.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/ECEA6FF1.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/IPVC PRESENTATION ID 392.vtt"}]},{"name":"ELIMINATION OF CERVICAL CANCER IN SETTINGS WITH ACTIVE HIV CONTROL: THE EXAMPLE OF TANZANIA \u003Csmall\u003E(ID 505)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":505,"presentation":"ELIMINATION OF CERVICAL CANCER IN SETTINGS WITH ACTIVE HIV CONTROL: THE EXAMPLE OF TANZANIA \u003Csmall\u003E(ID 505)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Michaela T. Hall (Australia)","photo":""},"playlist":[{"name":"ELIMINATION OF CERVICAL CANCER IN SETTINGS WITH ACTIVE HIV CONTROL: THE EXAMPLE OF TANZANIA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/P505_S1020_ELIMINATION OF CERVICAL CANCER.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/P505_S1020_ELIMINATION OF CERVICAL CANCER.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/C8705472.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/P505_S1020_ELIMINATION OF CERVICAL CANCER.vtt"}]},{"name":"ASSESSING TESTOSTERONE REPLACEMENT THERAPY WITH UNSATISFACTORY ANAL CYTOLOGY AND HISTOLOGICAL HIGH-GRADE ANAL LESIONS (HHSIL) IN OLDER MEN WHO HAVE SEX WITH MEN \u003Csmall\u003E(ID 1173)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1173,"presentation":"ASSESSING TESTOSTERONE REPLACEMENT THERAPY WITH UNSATISFACTORY ANAL CYTOLOGY AND HISTOLOGICAL HIGH-GRADE ANAL LESIONS (HHSIL) IN OLDER MEN WHO HAVE SEX WITH MEN \u003Csmall\u003E(ID 1173)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Dorothy J. Wiley (United States of America)","photo":""},"playlist":[{"name":"ASSESSING TESTOSTERONE REPLACEMENT THERAPY WITH UNSATISFACTORY ANAL CYTOLOGY AND HISTOLOGICAL HIGH-G","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/1173.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/1173.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/58A92776.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/1173.vtt"}]},{"name":"THE RISK OF HIV SEROCONVERSION FOLLOWING AN ANAL HPV INFECTION AMONG MSM \u003Csmall\u003E(ID 421)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":421,"presentation":"THE RISK OF HIV SEROCONVERSION FOLLOWING AN ANAL HPV INFECTION AMONG MSM \u003Csmall\u003E(ID 421)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Staci Sudenga (United States of America)","photo":""},"playlist":[{"name":"THE RISK OF HIV SEROCONVERSION FOLLOWING AN ANAL HPV INFECTION AMONG MSM","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200622-155537_Staci-Sude_2560x1440-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200622-155537_Staci-Sude_2560x1440-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/EE00B44D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/GMT20200622-155537_Staci-Sude_2560x1440-0.vtt"}]},{"name":"THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (1990-2015) \u003Csmall\u003E(ID 632)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":632,"presentation":"THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (1990-2015) \u003Csmall\u003E(ID 632)\u003C\/small\u003E","session":"Oral Session 10: HIV. Natural history and prevention in HIV-infected People","presenter":"Scott Beck (Canada)","photo":""},"playlist":[{"name":"THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (199","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/Scott Beck IPVC20 632 THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (1990-2015).mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/43\/Scott Beck IPVC20 632 THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (1990-2015).mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/3D67AC18.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/43\/Scott Beck IPVC20 632 THE INCIDENCE OF ANAL SQUAMOUS CELL CARCINOMA BY HIV AND MSM STATUS IN BRITISH COLUMBIA, CANADA (1990-2015).vtt"}]}]
{"type":2,"code":"6E32UU0K"}
[session]
[presentation]
[presenter]